Online citations, reference lists, and bibliographies.
← Back to Search

Targeting Of Drug‐loaded Nanoparticles To Tumor Sites Increases Cell Death And Release Of Danger Signals

Magdalena Alev, Laura Egenberger, L. Mühleisen, Bianca Weigel, B. Frey, R. Friedrich, Marina Poettler, C. Alexiou, C. Janko
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
ABSTRACT Innovative strategies fighting cancer by inducing anti‐tumor responses from the immune system are urgently needed. Amongst others, chemotherapeutics from the class of the anthracyclines have been shown to induce death of cancer cells with immunogenic features and triggering immunogenic anti‐tumor responses. However, the patient's immune system often becomes severely impaired by the unspecific action of these cytotoxic drugs in systemic chemotherapy, preventing any effective immune reactions. To reduce systemic side effects and to accumulate the drug exclusively in the tumor region, we developed an iron oxide nanoparticle‐based system for the magnetically targeted delivery of mitoxantrone to the tumor, which has previously proven its long‐term therapeutic efficacy in tumor bearing rabbits. Here, we show in vitro that superparamagnetic iron oxide nanoparticles (SPIONs), loaded with the chemotherapeutic drug mitoxantrone, are able to induce cell death with immunogenic features and concomitant maturation of dendritic cells, comparable to the free drug, whereas unloaded nanoparticles are very biocompatible. We conclude that the targeted delivery of mitoxantrone to the tumor region might be a promising possibility to selectively modulate the tumor microenvironment and to locally stimulate immune responses against the tumor. Thus, SPIONs can be used as a platform to specifically bring immunogenic cell death inducers (e.g. mitoxantrone, hypericin, doxorubicin) to the tumor region by sparing the immune system from their toxic effects.
This paper references
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
R. Stone (2001)
Differential Subcellular Distribution of Mitoxantrone in Relation to Chemosensitization in Two Human Breast Cancer Cell Lines
Sophie Vibet (2007)
Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?
C. Rébé (2015)
Early lymphopenia as a risk factor for chemotherapy‐induced febrile neutropenia
C. Choi (2003)
Toxicity of Mitoxantrone-loaded Superparamagnetic Iron Oxide Nanoparticles in a HT-29 Tumour Spheroid Model.
Annkathrin Hornung (2016)
Navigation to the graveyard-induction of various pathways of necrosis and their classification by flow cytometry.
C. Janko (2013)
Cytotoxic e ff ects of chemotherapy on cancer and immune cells : how can it be modulated to generate novel therapeutic strategies ?
M. M. Davis (2015)
M. Sankar (1824)
Cyclophosphamide and cancer: golden anniversary
A. Emadi (2009)
Visualization of superparamagnetic nanoparticles in vascular tissue using XμCT and histology
R. Tietze (2011)
Generation of an Optimized Polyvalent Monocyte-Derived Dendritic Cell Vaccine by Transfecting Defined RNAs after Rather Than before Maturation1
N. Schaft (2005)
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
A. Q. Sukkurwala (2014)
Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles
A. Ito (2003)
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
T. Panaretakis (2008)
M. Obeid (2007)
The in vitro immunogenic potential of caspase-3 proficient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation
Bernhard Kötter (2015)
The intersection between DNA damage response and cell death pathways.
S. Nowsheen (2012)
Chemotherapy‐induced neutropenia
J. Crawford (2004)
Scent of dying cells: the role of attraction signals in the clearance of apoptotic cells and its immunological consequences.
L. Munoz (2010)
Magnetic nanoparticle-based drug delivery for cancer therapy.
R. Tietze (2015)
Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids
Annkathrin Hornung (2015)
Dendritic cell-based therapeutic cancer vaccines: past, present and future
M. S. Ahmed (2014)
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.
I. Vermes (1995)
Consensus guidelines for the detection of immunogenic cell death
O. Kepp (2014)
DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
Dae-Seog Lim (2007)
UVB-irradiated apoptotic cells induce accelerated growth of co-implanted viable tumor cells in immune competent mice
R. Chaurio (2013)
Chemotherapy induces ATP release from tumor cells
I. Martins (2009)
Magnetic Iron Oxide Nanoparticles for Multimodal Imaging and Therapy of Cancer
R. Thomas (2013)
Targeted drug delivery to tumors: myths, reality and possibility.
Y. Bae (2011)
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu (2017)
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
H. Inoue (2014)
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
P. Sonneveld (1995)
Analysis of apoptosis by propidium iodide staining and flow cytometry
C. Riccardi (2006)
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Yuchen Fan (2015)
Immunotherapy of autoimmunity and cancer: the penalty for success
R. Caspi (2008)
Targeted drug delivery to tumors: myths
Y. H. Bae (2011)
determines the immunogenicity of chemotherapy - induced cancer cell death
K. Tani Inoue (2012)
Superparamagnetic iron oxide nanoparticles as novel X-ray enhancer for low-dose radiation therapy.
S. Klein (2014)
Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy
Po-Chin Liang (2016)
Treatment e ffi ciency of free and nanoparticle - loaded Mitoxantrone for magnetic drug targeting in multicellular tumor spheroids
C. Alexiou
Danger signalling during cancer cell death: origins, plasticity and regulation
Abhishek D Garg (2014)
Different Storage Conditions Influence Biocompatibility and Physicochemical Properties of Iron Oxide Nanoparticles
Jan Zaloga (2015)
Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution.
Zahra Hajihassan (2011)
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.
G. Schiavoni (2011)
Determination of the magnetic particle distribution in tumour tissue by means of x-ray tomography
O. Brunke (2006)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
R. Špíšek (2007)
The geriatric cancer patient: equal benefit from equal treatment.
L. Balducci (2001)
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
J. Zaloga (2016)
Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion.
Amelia E. Hochreiter-Hufford (2013)
Inflammatory outcomes of apoptosis
P. Davidovich (2014)
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.
Y. Ma (2013)
Studies on the adsorption and desorption of mitoxantrone to lauric acid/albumin coated iron oxide nanoparticles.
J. Zaloga (2018)
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy.
Xiao Zhao (2016)
Chemotherapy-induced neutropenia: risks
J. Crawford (2004)
Cellular immunotherapy: antigen recognition is just the beginning
D. Chen (2005)
Treatment e ffi ciency of free and nanoparticle - loaded Mitoxantrone for magnetic drug targeting in multicellular tumor spheroids
C. Alexiou
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
I. C. Henderson (1989)
[Dendritic cell-based therapeutic cancer vaccines].
M. Rizzo (2016)
No littering: the clearance of dead cells and leaking cellular contents and possible pathological complications
Jan Brauner (2013)
The Danger Model: A Renewed Sense of Self
P. Matzinger (2002)
Magnetic Nanoparticles in Cancer Theranostics
O. Gobbo (2015)
Clearance Deficiency and Cell Death Pathways: A Model for the Pathogenesis of SLE
A. Mahajan (2016)
Superparamagnetic Iron Oxide Nanoparticles: Amplifying ROS Stress to Improve Anticancer Drug Efficacy
G. Huang (2013)
HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
M. Šírová (2013)
Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment
C. Pan (2018)
Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death
I. Martins (2012)
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin
Abhishek D Garg (2011)
Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility
J. Zaloga (2014)
Damage associated molecular pattern molecules.
M. Lotze (2007)
Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy
Adam J. Litterman (2013)
Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.
D. Vyas (2015)
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P Dunn (2002)
Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes
C. Janko (2013)
Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
Amani Makkouk (2015)
Cytotoxic e ff ects of chemotherapy on cancer and immune cells : how can it be modulated to generate novel therapeutic strategies ?
M. M. Davis (2015)
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
E. Vacchelli (2015)
Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids.
J. Lown (1985)
J. Lackie (2013)
Doxorubicin-Hyaluronan conjugated superparamagnetic Iron oxide nanoparticles (DOX-HA-SPION) enhanced cytoplasmic uptake of doxorubicin and modulated apoptosis
D. Vyas (2015)
Interaction of mitoxantrone
Z. Hajihassan (2011)
Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits.
R. Tietze (2013)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesnière (2010)
Characterization of the fluorescence of the antitumor agent, mitoxantrone.
D. Bell (1988)
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
M. Elliott (2009)
Inflammatory outcomes of apoptosis, necrosis and necroptosis
P. Davidovich (2014)
The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
R. Chaurio (2014)
Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation.
S. Klein (2012)
Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.
Stephan Duerr (2012)
Topoisomerase enzymes as therapeutic targets for cancer chemotherapy.
G. Giles (2005)
Calreticulin exposure dictates the immunogenicity of cancer cell death
M. Obeid (2007)
Microcomputed tomography analysis of ferrofluids used for cancer treatment.
H. Rahn (2008)
Nanodrugs: pharmacokinetics and safety
S. Onoue (2014)
Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery.
N. Elbialy (2015)
Magnetic nanoparticles for cancer therapy
Stephan Duerr (2013)
Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy.
Y. Wang (2006)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar